Faron Pharmaceuticals Oy (FARN) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free FARN Stock Alerts GBX 230 +15.00 (+6.98%) (As of 03:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 6:07 AM | americanbankingnews.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Above 50 Day Moving Average of $140.22April 30, 2024 | marketwatch.comFaron Pharmaceuticals Oy Appoints Juho Jalkanen as CEOApril 16, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Confirms Plans for the Coming Months Under New LeadershipApril 16, 2024 | finance.yahoo.comFaron Confirms Plans for the Coming Months Under New LeadershipMarch 18, 2024 | finance.yahoo.comInside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AMLMarch 18, 2024 | finance.yahoo.comFaron Pharmaceuticals reports promising phase 1 results from BEXMAB studyMarch 14, 2024 | finance.yahoo.comFaron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of BexmarilimabMarch 13, 2024 | finance.yahoo.comFaron’s Financial Statement Release January 1 to December 31, 2023March 4, 2024 | uk.investing.comFaron Pharma secures €3.2 million convertible loanFebruary 19, 2024 | finanznachrichten.deNasdaq Helsinki Ltd: THE SHARES OF FARON PHARMACEUTICALS LTD. GIVEN OBSERVATION STATUSFebruary 1, 2024 | uk.investing.comFaron Pharmaceuticals Oy (FARN)January 25, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 25, 2024 | finance.yahoo.comDetailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 23, 2024 | finance.yahoo.comFaron Pharmaceuticals Oy (FARN.L)January 11, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB TrialJanuary 3, 2024 | finance.yahoo.comFaron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 11, 2023 | finance.yahoo.comFaron Pharmaceuticals presents "very positive" Phase 1 data at ASH ConferenceDecember 11, 2023 | lse.co.ukFaron Pharmaceuticals hails positive results of cancer drug trialDecember 11, 2023 | finance.yahoo.comInside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual MeetingDecember 7, 2023 | finance.yahoo.comFaron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports MedicineNovember 24, 2023 | morningstar.comFaron Pharmaceuticals Oy FARNNovember 6, 2023 | finance.yahoo.comFaron Pharmaceuticals initiates second phase of BEXMAB studyNovember 6, 2023 | finance.yahoo.comFaron Pharmaceuticals Oy's (LON:FARN) last week's 11% decline must have disappointed individual investors who have a significant stakeNovember 2, 2023 | finance.yahoo.comFaron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual MeetingOctober 27, 2023 | proactiveinvestors.comFaron Pharma raises €7.1m as cancer study continues apaceOctober 27, 2023 | finance.yahoo.comInside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade RegisterOctober 16, 2023 | proactiveinvestors.comFaron Pharmaceuticals' chief speaks after latest promising BEXMAB trial dataOctober 11, 2023 | proactiveinvestors.comFaron Pharma data 'extremely encouraging', says CEOOctober 11, 2023 | proactiveinvestors.comFaron Pharmaceuticals data 'highly encouraging', say bankOctober 11, 2023 | finance.yahoo.comInside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS PatientsOctober 3, 2023 | finance.yahoo.comFaron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 MonthsSeptember 26, 2023 | finance.yahoo.comBreakeven On The Horizon For Faron Pharmaceuticals Oy (LON:FARN)September 22, 2023 | markets.businessinsider.comFaron Pharmaceuticals Ltd Results of the Extraordinary General MeetingSeptember 22, 2023 | finance.yahoo.comFaron Pharmaceuticals Announces Board ChangesSeptember 22, 2023 | finance.yahoo.comFaron Pharmaceuticals Ltd Results of the Extraordinary General MeetingSeptember 21, 2023 | reuters.comBRIEF-Faron Pharmaceuticals Appoints Birge Berns As Interim Chief Medical OfficerSeptember 21, 2023 | proactiveinvestors.comFaron Pharma appoints new chief medical officerSeptember 21, 2023 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical OfficerSeptember 21, 2023 | finance.yahoo.comFaron Appoints Dr. Birge Berns, MD as Interim Chief Medical OfficerSeptember 6, 2023 | finance.yahoo.comFaron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 1, 2023 | finance.yahoo.comFaron Pharmaceuticals kicks off second half with FDA announcementAugust 30, 2023 | finance.yahoo.comFaron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 98% Above Its Share PriceAugust 29, 2023 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid LeukemiaAugust 29, 2023 | finance.yahoo.comFaron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid LeukemiaAugust 29, 2023 | finance.yahoo.comFaron Reports Half-Year Financial Results, January 1 – June 30, 2023August 4, 2023 | finance.yahoo.comFaron Pharmaceuticals Notice of Half-Year Financial ResultsAugust 2, 2023 | finance.yahoo.comFaron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 25, 2023 | finance.yahoo.comFaron Pharmaceuticals hoping for first filing of BLA in H1 2025July 19, 2023 | finance.yahoo.comFaron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study UpdateJuly 19, 2023 | finance.yahoo.comFaron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. FARN Media Mentions By Week FARN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FARN News Sentiment▼0.000.57▲Average Medical News Sentiment FARN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FARN Articles This Week▼11▲FARN Articles Average Week Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Futura Medical News Scancell News Poolbeg Pharma News Redx Pharma News e-therapeutics News Avacta Group News Arecor Therapeutics News C4X Discovery News Arix Bioscience News Sareum News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:FARN) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis 1 Biotech Stock has been shocking the marketsHuge AlertsDoes this make you sick?Allegiance GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.